Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Next

Ozlem Tureci, the co-founder of BioNTech, hopes to apply the company's SARS-CoV-2 vaccine success to its initial work developing cancer vaccines, the Associated Press reports.

It adds that, with the pandemic, Tureci and Ugur Sahin, her husband and BioNTech co-founder, switched from working on cancer vaccines to one for SARS-CoV-2. As the AP notes, the Pfizer-BioNTech SARS-CoV-2 vaccine received authorization in the UK and US less than a year later.

"It pays off to make bold decisions and to trust that if you have an extraordinary team, you will be able to solve any problem and obstacle which comes your way in real time," Tureci tells the AP. It adds that among the problems BioNTech faced were conducting large, global clinical trials and ramping up manufacturing.

The AP says BioNTech can use the experience and funds it now has for its cancer vaccine research. Tureci tells it that they have a number of mRNA-based cancer vaccines in the works and expects that they may be able to give them to patients in a few years.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.